Christopher Bristow

h-index

Research activity per year

Fingerprint

Dive into the research topics where Christopher Bristow is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

73 Article
2 Paper
1 Comment/debate

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
House, N. C., Chen, M. M., Khazaei, S., Brown, V., Ramsden, P., Peng, D. H., Moore, S., Yuan, L., Wu, R., Wang, F., Luo, L., Feng, N., Bristow, C. A., Yap, T. A., Keyomarsi, K., Marszalek, J. R., Ribich, S., Rinne, M. L., Muthuswamy, L. B. & Faia, K. L., Dec 2025, In: npj Breast Cancer. 11, 1, 135.
Research output: Contribution to journal › Article › peer-review

Open Access
4 Link opens in a new tab Scopus citations
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
Pilié, P. G., Giuliani, V., Wang, W. L., McGrail, D. J., Bristow, C. A., Ngoi, N. Y. L., Kyewalabye, K., Wani, K. M., Le, H., Campbell, E., Sanchez, N. S., Yang, D., Gheeya, J. S., Goswamy, R. V., Holla, V., Shaw, K. R., Meric-Bernstam, F., Liu, C. Y., Ma, X. Y. & Feng, N. & 31 others, Machado, A. A., Bardenhagen, J. P., Vellano, C. P., Marszalek, J. R., Rajendra, E., Piscitello, D., Johnson, T. I., Likhatcheva, M., Elinati, E., Majithiya, J., Neves, J., Grinkevich, V., Ranzani, M., Luzarraga, M. R., Boursier, M., Armstrong, L., Geo, L., Lillo, G., Tse, W. Y., Lazar, A. J., Kopetz, S. E., Do, M. K. G., Lively, S., Johnson, M. G., Robinson, H. M. R., Smith, G. C. M., Carroll, C., Di, M. E. F., Jones, P., Heffernan, T. P. & Yap, T. A., May 15 2024, In: Clinical Cancer Research. 30, 10, p. 2121-2139 19 p.
Research output: Contribution to journal › Article › peer-review

Open Access
11 Link opens in a new tab Scopus citations
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
Jung, P., Glaser, S. P., Han, J., Popa, A., Pisarsky, L., Feng, N., Geyer, A., Haderk, F., Alpar, D., Bristow, C., Schmittner, S., Traexler, P. E., Mahendra, M., Poehn, B., Gandhi, P., Fiorelli, R., Awate, S., Budano, N., Martin, F. & Albrecht, C. & 12 others, Drobits-Handl, B., Anand, S. S., Kasturirangan, S., Trapani, F., Schweifer, N., Marszalek, J. R., Tontsch-Grunt, U., Pearson, M., Heffernan, T. P., Kraut, N., Vellano, C. P. & García-Martínez, J. M., 2024, In: mAbs. 16, 1, 2438173.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Link opens in a new tab Scopus citations
Co-targeting SOS1 enhances the antitumor effects of KRAS^G12C inhibitors by addressing intrinsic and acquired resistance
Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C. A., Albrecht, C., Alpar, D., Arnhof, H., Bergner, O., Bosch, K., Feng, N., Gao, S., Gerlach, D., Gmachl, M., Hinkel, M., Lieb, S., Jeschko, A., Machado, A. A., Madensky, T. & Marszalek, E. D. & 18 others, Mahendra, M., Melo-Zainzinger, G., Molkentine, J. M., Jaeger, P. A., Peng, D. H., Schenk, R. L., Sorokin, A., Strauss, S., Trapani, F., Kopetz, S., Vellano, C. P., Petronczki, M., Kraut, N., Heffernan, T. P., Marszalek, J. R., Pearson, M., Waizenegger, I. C. & Hofmann, M. H., Sep 2024, In: Nature Cancer. 5, 9, p. 1352-1370 19 p.
Research output: Contribution to journal › Article › peer-review

Open Access
32 Link opens in a new tab Scopus citations
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAF^V600E-Mutated Colorectal Cancer
Lee, H. M., Saw, A. K., Morris, V. K., Napolitano, S., Bristow, C., Srinivasan, S., Peoples, M., Sorokin, A., Marie, P. K., Schulz, J., Singh, A. K., Terranova, C., Coker, O., Jain, A., Kopetz, S. & Rai, K., Nov 15 2024, In: Clinical Cancer Research. 30, 22, p. 5166-5179 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
10 Link opens in a new tab Scopus citations

Christopher Bristow

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer

Co-targeting SOS1 enhances the antitumor effects of KRAS^G12C inhibitors by addressing intrinsic and acquired resistance

Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAF^V600E-Mutated Colorectal Cancer

Christopher Bristow

Fingerprint

Collaborations and top research areas from the last five years

Research output

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer

Co-targeting SOS1 enhances the antitumor effects of KRAS^G12C inhibitors by addressing intrinsic and acquired resistance

Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAF^V600E-Mutated Colorectal Cancer